Establishment of the
company
OUR VISION
An integrated global R&D biopharma to discover and develop innovative
medicines for patients worldwide
medicines for patients worldwide
Immunophage is a clinical-stage biotech company focusing on discovering, developing, and commercializing innovative drugs globally for patients worldwide. The company strengthens its R&D pipeline by continually exploring novel disease pathophysiology, refining new targets, and discovering small-molecule or large-molecule drugs. Immunophage aims to advance two innovative programs into clinical trials every year by combining internal R&D expertise and partnerships with global biopharmaceutical companies.
Collaboration
Innovation
Passion
Integrity
Prudence
Dr. Fan, President and CEO of Immunophage Biotech Co., Ltd., has an impressive background in biomedical research. In 2010, he Joined GSK R&D China as an Associate Director and was later appointed Adjunct Professor at Tongji University. In 2016, he became the Deputy Dean of the School of Translational Medicine, and Director of the Biomedical Research Center at Nanchang University, when he founded Immunophage Biotech Co., Ltd.
Dr. Fan is a renowned cancer biology and neurobiology expert, having published over 60 papers in peer-reviewed international journals and holding over 20 patents. His contributions have been recognized through various prestigious awards, including the National Natural Science Award (2002), the Chinese Medical Science Award (2001), and the Specialized Neuroscience Research Award from the NIH, USA (2007). He has also been honored as a scholar of "The Alexander Von Humboldt Fellowship" in Germany and a scholar of the "One-hundred Talent Program" by the Chinese Academy of Sciences.
Dr. Fan earned his M.D. and Ph.D. degrees from Shanghai Jiao Tong University School of Medicine in 1996. Following his doctoral studies, he underwent six years of postdoctoral training at the Chinese Academy of Sciences, the University of Wuerzburg, and Vanderbilt University. In 2002, he was appointed Research Assistant Professor at Vanderbilt University School of Medicine. Subsequently, in 2004, Dr. Fan became an Assistant Professor (tenure track) at Meharry Medical College, holding a secondary Assistant Professor position at Vanderbilt University School of Medicine. He was promoted to Associate Professor at Meharry Medical College in 2007 and later joined Virginia Commonwealth University School of Medicine as an Associate Professor in 2008.
+
Dr. Wang is a Senior Physician in Comparative Medicine, a Professor at the CAS Shanghai Institute of Biological Sciences (adjunct), and a Distinguished Professor at Yunnan Agricultural University. He is a seasoned executive with solid knowledge of both small and large-molecule drugs, boasting enormous experience in program insight for shaping R&D strategy, with over 30 years of translational medicine research and team management experience in multinational pharmaceutical companies.
During his tenure at GSK R&D China, Dr. Wang established an integrated preclinical platform, providing comprehensive support for target identification, validation, lead compound optimization, pharmacodynamics, pharmacokinetic studies, discovery histopathology, safety assessment, and blood-brain barrier penetration for several dozens of projects, enabling them to proceed to candidate selections and clinical trials. Due to his distinguished contributions, Dr. Wang received many awards from GSK R&D China. He also served as a core member of the GSK global translational medicine leadership team. He was elected as a Senior GSK Fellow, the highest level of scientific research scholar at the company.
Dr. Wang's remarkable contributions to translational medicine and drug discovery have earned him numerous awards and recognition from national and international organizations. He has published over 70 papers in prestigious international journals and holds multiple patents. Dr. Wang received his Ph.D. in Molecular cell biology from the University of Calgary in Canada. He completed his residency in Comparative Medicine at the University of Pennsylvania in the USA and conducted postdoctoral research on rheumatoid arthritis at Harvard Medical School. Before his return to China, he served as faculty in the Department of Surgery at the Faculty of Medicine at the University of Alberta, Canada.
+
Ms. Tao holds important positions as a Board Member, Secretary of the Board, and Head of Human Resources at Immunophage. As Secretary of the Board, she oversees various critical aspects, including financing, license-out, public relations, and overall company operations.
As Head of Human Resources, she manages human resources, compliance management, environmental health and safety (EHS), and other operational matters. With over 15 years of experience in human resource management within globally recognized pharmaceutical companies, Ms. Tao brings extensive expertise in global talent recruitment and development, EHS, administration, and operations.
Ms. Tao completed her undergraduate studies in Animal Medicine at Shanghai Jiao Tong University and obtained her MPA (Master of Public Administration) from Shanghai Normal University. Additionally, she holds certifications as a Level II Human Resource Manager and an Economist (Medium Grade).
+
Mr. Zhang brings more than ten years of valuable knowledge and experience in drug discovery & development, primarily gained through his tenure at GSK and other prominent pharmaceutical companies. His expertise lies in integrated biological platform science, where he has played a crucial role.
In 2010, Mr. Zhang joined GSK, where his primary focus shifted to laboratory animal science. He excelled in developing various animal models for drug discovery, earning him special recognition by obtaining an Exceptional Science Award (ESA) from GSK.
In 2009, Mr. Zhang received a Master's degree in Biochemistry and Molecular Biology from the Chinese Academy of Military Medical Sciences and Fujian Agricultural and Forestry University. Following his graduation, he focused his research on gene Cloning, protein expression, protein purification, and the establishment of monoclonal antibody establishment at the Shanghai Institute of Nutrition, Chinese Academy of Sciences.
+
Dr. Liu brings extensive expertise and knowledge in neurodegenerative diseases, with over 15 years of research experience. As the Supervisor and Head of the Neurology & Business Department, she is pivotal in overseeing preclinical pharmacology and efficacy studies in the neuroscience field.
Dr. Liu completed her Ph.D. at the Institute of Neuroscience, Chinese Academy of Sciences. After her doctoral studies, she pursued three years of postdoctoral training at the Shanghai Institutes for Biological Sciences. Before joining Immunophage, Dr. Liu served as a professor at Guangxi Medical University, where she gained four years of valuable work experience. Her research contributions were recognized through receiving two grants from the National Natural Science Foundation.
+
Dr. Wang, as the Head of the Oncology Department, brings extensive expertise in tumor immunotherapy from his more than ten years of experience in multinational pharmaceutical companies. He is responsible for target identification, target validation, and animal model development for antitumor efficacy in vivo.
Dr. Wang received his Ph.D. from the Wuhan Institute of Virology, Chinese Academy of Science, further strengthening his knowledge in oncology.
+
Mr. Li has over 10 years of experience in autoimmune disease research, with previous positions at the Institut Pasteur of Shanghai Chinese Academy of Sciences and the Institute of Life Sciences at Zhejiang University.
He received a Master of Biochemistry and Molecular Biology from the Institut Pasteur of Shanghai Chinese Academy of Sciences & Shanghai University.
+
As the Head of the Medicinal Chemistry Department, Dr. Li brings over ten years of experience in academic and industrial small molecule drug discovery. His expertise encompasses various aspects of the drug discovery process, including early hit/lead identification, structure/ligand-based drug design, and lead optimization leading to candidate molecule selection. At Immunophage, Dr. Li oversees the operation and management of the medicinal chemistry team.
Dr. Li holds a Ph.D. in Chemistry from Kyoto University, Japan, and has received postdoctoral training at The Scripps Research Institute, further enhancing his knowledge and skills in medicinal chemistry.
+
As the Head of the Medicinal Chemistry Project Management , Dr. Mo holds a Ph.D. from Fudan University, China.
Director, Medicinal Chemistry Department, Plastech Pharmaceutical Technology Co. Ltd.,
Research Investigator, Shanghai Tuojie Biotech Co. Ltd .,
Senior Scientist, Shanghai ChemPartner Co. Ltd.,
+
Ms. Wang, as the Head of the Antibody Screening Department, brings more than 16 years of experience in antibody-drug screening from her work in internationally renowned pharmaceutical companies. She has successfully established an antibody development process tailored for GPCR targets and a high-throughput screening system. In her role, Ms. Wang is responsible for the daily operations of the antibody screening platform.
Ms. Wang obtained a Master's degree in Biochemistry from Zhejiang University, solidifying her foundation in antibody development and screening.
+
Dr. Gao, the Head of the Clinical Operation Department, boasts an impressive track record of over 14 years in new drug development. Before joining Immunophage, he gained experience from prestigious institutions and organizations such as Shanghai 6th People Hospital, Quintiles, Covance, Clinipace, Wuxi CDS, Syneos, and Alpha Biopharma. His extensive experience in various therapeutic areas of clinical trials includes oncology, neuroimmune disorders, urology, nephrology, arthralgia, and obstetrics.
Dr. Gao has actively participated in numerous global and local phase I to III studies, with at least one investigational product he was involved in currently undergoing NDA filing.
Dr. Gao obtained his Master's degree from Shanghai Jiaotong University School of Medicine, solidifying his academic foundation and medical expertise.
+
Cpyright © 2023 Nanjing Immunophage Biotech Co.,Ltd All Rights Reserved.
